Various genetic abnormalities were detected by the Luna Prenatal Test over the course of the study, including common trisomies, rare autosomal trisomies, microdeletions, microduplications and confined placental mosaicism.
TORONTO (PRWEB)
March 06, 2023
For decades, many groups around the world have pursued the isolation and genetic analysis of circulating fetal cells from maternal peripheral blood as an improved form of noninvasive prenatal testing. However, the exceeding rarity of these cells in the blood of pregnant women has proven a challenging obstacle in the establishment of a reliable test methodology.
Luna Genetics has overcome this challenge using a unique combination of robust immunostaining, microfluidic enrichment, automated microscopy and single cell isolation. The noninvasive prenatal testing method was validated with over 200 high-risk cases undergoing chorionic villus sampling (CVS) or amniocentesis, along with 158 low-risk cases not undergoing CVS or amniocentesis. The Luna Prenatal Test showed near-perfect concordance with the CVS and amniocentesis results, and the few discordant cases were consistent with current knowledge of confined placental mosaicism. Various genetic abnormalities were detected by the Luna Prenatal Test over the course of the study, including common trisomies, rare autosomal trisomies, microdeletions, microduplications and confined placental mosaicism.
Furthermore, the Luna Prenatal Test methodology has been successfully applied to the identification of recessive monogenic disorders. In collaboration with Juno Genetics, the Luna Prenatal Test isolated circulating fetal cells from a pregnancy at risk of Walker-Warburg Syndrome. The cells were shipped overnight to Juno Genetics for sequencing and haplotype-based analysis of the POMT1 gene. The fetus was determined to be an unaffected heterozygous carrier of the POMT1 c.2167dupG allele, with concordant CVS results reported 10 days later. This case study demonstrates proof-of-concept for the application of the Luna Prenatal Test in detecting monogenic disorders early in pregnancy.
Register today to learn about a breakthrough in the reliable isolation and successful analysis of circulating fetal cells for noninvasive prenatal testing early in pregnancy. The webinar will include the path taken to establish the Luna Prenatal Test methodology, data from key validation cases and the future trajectory of the test.
Disclaimer: Namocell products are for research use only; not for diagnostic purposes.
Join Mason Ouren, R&D Scientist, Luna Genetics, for the live webinar on Friday, March 17, 2023, at 2pm EDT (11am PDT).
For more information, or to register for this event, visit Noninvasive Prenatal Testing: The Luna Prenatal Test for Isolation of Circulating Fetal Cells Early in Pregnancy.
Registrants will be provided with on-demand access to the webinar recording after the event.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com
Share article on social media or email: